New kidney biomarkers to predict kidney injury after radical nephrectomy
Novel Biomarkers to Predict Acute Kidney Injury and Chronic Kidney Disease After Radical Nephrectomy: an Exploratory Prospective Cohort Study
Peking University First Hospital · NCT07088874
We will test whether measuring new kidney biomarkers before, during, and after radical nephrectomy can help predict acute kidney injury and one-year chronic kidney disease in adults having the operation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University First Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07088874 on ClinicalTrials.gov |
What this trial studies
This observational study will enroll adults undergoing unilateral radical nephrectomy at Peking University First Hospital and collect perioperative blood and urine samples to measure novel renal injury, stress, and functional biomarkers. Researchers will use standard KDIGO criteria (serum creatinine and urine output) as the clinical reference and compare how well the novel biomarkers predict postoperative acute kidney injury. Participants will be followed for one year to determine whether early biomarker changes predict longer-term chronic kidney disease. The goal is to define which perioperative biomarker patterns offer added predictive value beyond traditional measures.
Who should consider this trial
Good fit: Adults (age ≥18) scheduled for unilateral radical nephrectomy who do not have a solitary kidney or severe preexisting kidney failure (CKD stage G4–G5, eGFR <30 mL/min/1.73 m²) and who can attend perioperative sampling and follow-up visits are ideal candidates.
Not a fit: Patients with a solitary kidney, severe preexisting kidney failure (GFR <30 mL/min/1.73 m²), or those requiring vena cava thrombectomy are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the findings could enable earlier and more accurate detection of postoperative AKI and help guide interventions to reduce long-term kidney decline after nephrectomy.
How similar studies have performed: Biomarker approaches (e.g., NGAL, KIM-1, TIMP-2•IGFBP7) have shown promise for predicting AKI in other surgical settings, but their utility specifically around radical nephrectomy is less well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years; * Scheduled to undergo unilateral radical nephrectomy. Exclusion Criteria: * Solitary kidney; * Preoperative diagnosis of chronic kidney disease stages G4 or G5 (GFR \<30 mL/min/1.73m²); * Tumor invasion of the vena cava requiring thrombectomy; * Other conditions deemed by the investigator as unsuitable for participation in this study.
Where this trial is running
Beijing, Beijing Municipality
- Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Qiongfang Wu, MD
- Email: wuqf91@163.com
- Phone: 8610 83572460
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Nephrectomy, Acute Kidney Injury, Biomarker